<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127269</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_04980</org_study_id>
    <secondary_id>U1111-1116-9268</secondary_id>
    <nct_id>NCT01127269</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes</brief_title>
  <acronym>AFICIONADO</acronym>
  <official_title>Practical Implementation of ADA/EASD Consensus Algorithm in Patients With Type 2 Diabetes: Timely Insulin Initiation and Titration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) &lt; 7% with no severe or
      nocturnal hypoglycemic episodes at 6 months

      Secondary Objectives:

        -  Glycosylated Hemoglobin (HbA1c) change from baseline to 6 months

        -  Insulin glargine dose at 3 and 6 months

        -  Hypoglycemic episodes (all types)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Glycosylated Haemoglobin (HbA1c) &lt;7% with no severe documented nocturnal hypoglycemia episode.</measure>
    <time_frame>From week 0 (baseline) to week 24 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>From week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and timing of insulin glargine</measure>
    <time_frame>From week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>From week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.
Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with a diagnosis of type 2 diabetes for more than 6 months

          -  Patients treated with Oral AntiDiabetics (OADs monotherapy or combination) with an
             HbA1c &gt;7% and &lt;10% and/or treated with NPH insulin with HbA1c &gt;7% and &lt;10% or treated
             with NPH insulin who have experienced severe and/or nocturnal hypoglycemia in the last
             6 months.

          -  Ability to perform SMBS and insulin self-titration under the physicians guidance.

          -  Body Mass Index (BMI) &gt;21 kg/ m2.

          -  Signature of informed consent.

        Exclusion criteria:

          -  Hospitalized patients.

          -  Pregnant women or with the intention of becoming pregnant.

          -  Unexplained weight loss of more than 10% in the last 6 months.

          -  Women with child bearing potential not using effective contraceptive methods.

          -  Women in breast feeding period.

          -  Patients on chronic treatment with systemic corticosteroids or protease inhibitors.

          -  History of drug or alcohol abuse.

          -  Diabetic retinopathy with surgical treatment in 3 months previous to study entry or
             patients that could require surgical treatment in the following 6 months to study
             entry.

          -  Major systemic disease clinically important that would interfere with implementation
             or interpretation of the study, at the discretion of the investigator.

          -  Renal failure known as creatinine &gt; 1.4 mg/dl in women and &gt; 1.5 mg/dl in men.

          -  Known hypersensitivity to glargine or any of its excipients.

          -  Patients with history of hospitalization due to cardiovascular event, cardiovascular
             procedure in the past 6 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 10</name>
      <address>
        <city>C.a.b.a.</city>
        <zip>C1050AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 14</name>
      <address>
        <city>C.a.b.a.</city>
        <zip>C1419AHN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 01</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 11</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9</name>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 06</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 15</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 16</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 18</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 26</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 22</name>
      <address>
        <city>Mar del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 13</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7602CBM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 02</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 021</name>
      <address>
        <city>Moreno -Pcia. de Bs. As.-</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 07</name>
      <address>
        <city>Morón</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 04</name>
      <address>
        <city>Paraná</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 05</name>
      <address>
        <city>Sarandí</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 20</name>
      <address>
        <city>Tandil</city>
        <zip>7000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 25</name>
      <address>
        <city>Zárate</city>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

